PMID- 15043465
OWN - NLM
STAT- MEDLINE
DCOM- 20040719
LR  - 20210527
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 128
IP  - 4
DP  - 2004 Apr
TI  - Cellular proliferative fraction measured with topoisomerase IIalpha predicts 
      malignancy in endocrine pancreatic tumors.
PG  - 426-9
AB  - CONTEXT: Endocrine pancreatic tumors (EPTs) are rare lesions with varying 
      biological behavior. Establishing malignancy is a challenge for clinicians and 
      pathologists. OBJECTIVE: To establish the role of proliferative, apoptotic, 
      angiogenic, and hormonal markers as predictors of malignancy in EPTs. DESIGN: 
      Paraffin-embedded EPT samples were studied for prognostic markers. PATIENTS: 
      Twenty-one consecutive patients with a diagnosis of EPT. MAIN OUTCOME MEASURES: 
      The proliferative fraction (topoisomerase IIalpha), microvascular density (CD34), 
      vascular endothelial growth factor expression, and estrogen receptor-beta 
      (ERbeta) expression were studied by immunohistochemistry on all EPTs. Apoptosis 
      was also assessed with terminal deoxynucleotidyl transferase nick-end labeling. 
      RESULTS: We identified 13 benign and 8 malignant tumors. Topoisomerase IIalpha 
      was significantly increased in malignant tumors (P =.001), while there were no 
      differences in apoptosis, microvascular density, or vascular endothelial growth 
      factor expression in association with malignancy. No correlation could be 
      identified between microvascular density and vascular endothelial growth factor 
      expression, and ERbeta was not detected. A receiver operating characteristic 
      curve for topoisomerase IIalpha disclosed that above a labeling index of 13, the 
      test had 88% sensitivity and 100% specificity for predicting malignancy. 
      CONCLUSION: Cellular proliferation measured with topoisomerase IIalpha is a 
      simple prognostic marker for malignancy in EPTs, unlike apoptosis, angiogenesis, 
      or the presence of ERbeta, which were not associated with malignant behavior. 
      These findings designate a defined field for future research on endocrine 
      pancreatic carcinogenesis and a possible target for chemotherapeutic agents.
FAU - Diaz-Rubio, Jose Luis
AU  - Diaz-Rubio JL
AD  - Department of Gastroenterology, Instituto Nacional de Ciencias Medicas y 
      Nutricion Salvador Zubiran, Mexico City, Mexico.
FAU - Duarte-Rojo, Andres
AU  - Duarte-Rojo A
FAU - Saqui-Salces, Milena
AU  - Saqui-Salces M
FAU - Gamboa-Dominguez, Armando
AU  - Gamboa-Dominguez A
FAU - Robles-Diaz, Guillermo
AU  - Robles-Diaz G
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Estrogen Receptor beta)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, Neoplasm
MH  - Apoptosis
MH  - Biomarkers, Tumor/*analysis
MH  - Cell Division
MH  - DNA Topoisomerases, Type II/*analysis
MH  - DNA-Binding Proteins
MH  - Estrogen Receptor beta
MH  - Female
MH  - Gastrinoma/blood supply/enzymology/*pathology
MH  - Humans
MH  - In Situ Nick-End Labeling
MH  - Insulinoma/blood supply/enzymology/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/*analysis
MH  - Neovascularization, Pathologic/pathology
MH  - Pancreatic Neoplasms/enzymology/*pathology
MH  - Prognosis
MH  - ROC Curve
MH  - Receptors, Estrogen/analysis
MH  - Sensitivity and Specificity
MH  - Vascular Endothelial Growth Factor A/analysis
EDAT- 2004/03/27 05:00
MHDA- 2004/07/20 05:00
CRDT- 2004/03/27 05:00
PHST- 2004/03/27 05:00 [pubmed]
PHST- 2004/07/20 05:00 [medline]
PHST- 2004/03/27 05:00 [entrez]
AID - OA3222 [pii]
AID - 10.5858/2004-128-426-CPFMWT [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2004 Apr;128(4):426-9. doi: 10.5858/2004-128-426-CPFMWT.